You are here

cystic fibrosis

Pharmas That Own Their Markets

Pharmas That Own Their Markets

Forbes

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Vertex Faces Choice After Second CF Drug Combo Succeeds in Phase 3

Vertex Faces Choice After Second CF Drug Combo Succeeds in Phase 3

Xconomy

Vertex Pharmaceuticals

cystic fibrosis

clinical trials

Flag link:

Vertex CEO, CCO head for U.K. hearing on Orkambi pricing standoff

Vertex CEO, CCO head for U.K. hearing on Orkambi pricing standoff

Fierce Pharma

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress

‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress

Stat

cystic fibrosis

drug development

Flag link:

Cystic fibrosis patients lobby Vertex to drop drug prices

Cystic fibrosis patients lobby Vertex to drop drug prices

Pharmaforum

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Talee Bio Receives $4.5 Million from the Cystic Fibrosis Foundation to Expedite Development of Two Gene Therapy Candidates

Talee Bio Receives $4.5 Million from the Cystic Fibrosis Foundation to Expedite Development of Two Gene Therapy Candidates

CP Wire

cystic fibrosis

Flag link:

Talee Bio Receives $4.5 Million from the Cystic Fibrosis Foundation to Expedite Development of Two Gene Therapy Candidates

cystic fibrosis

Flag link:

European Commission Approves Kalydeco to Treat Cystic Fibrosis

European Commission Approves Kalydeco to Treat Cystic Fibrosis

CP Wire

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

European Commission Approves Kalydeco to Treat Cystic Fibrosis

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Vertex cystic fibrosis drug combination shows strong results in pivotal clinical trials

Vertex cystic fibrosis drug combination shows strong results in pivotal clinical trials

Stat

Vertex Pharmaceuticals

cystic fibrosis

clinical trials

VX-659 + tezacaftor + ivacaftor

Flag link:

Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval

Upcoming events – Vertex awaits triplet data and GBT seeks approval for approval

EP Vantage

cystic fibrosis

Global Blood Therapeutics

sickle cell disease

Flag link:

AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated

AbbVie Takes Aim at Vertex Pharmaceuticals Incorporated

Motley Fool

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

AbbVie Takes Over Galapagos Cystic Fibrosis Collaboration Instead of Walking Away

AbbVie Takes Over Galapagos Cystic Fibrosis Collaboration Instead of Walking Away

BioSpace

cystic fibrosis

Flag link:

Vertex Receives Positive Opinion from CHMP for Kalydeco in Patients 12 to 24 months wth Cystic Fibrosis

Vertex Receives Positive Opinion from CHMP for Kalydeco in Patients 12 to 24 months wth Cystic Fibrosis

CP Wire

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Synspira's Cystic Fibrosis Treatment Receives Orpan Drug Designation

Synspira's Cystic Fibrosis Treatment Receives Orpan Drug Designation

CP Wire

cystic fibrosis

Flag link:

Synspira's Cystic Fibrosis Treatment Receives Orpan Drug Designation

cystic fibrosis

Flag link:

Vivus, diving into the cystic fibrosis sphere, backs stadium step-climbing fundraiser

Vivus, diving into the cystic fibrosis sphere, backs stadium step-climbing fundraiser

Fierce Pharma

cystic fibrosis

Flag link:

Mylan Strikes $463 Million Deal With Novartis for CF Product Line

Mylan Strikes $463 Million Deal With Novartis for CF Product Line

BioSpace

cystic fibrosis

Flag link:

Vertex Completes Enrollment of Two Ph III Studies of Cystic Fibrosis Drug Combination

Vertex Completes Enrollment of Two Ph III Studies of Cystic Fibrosis Drug Combination

CP Wire

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Vertex Completes Enrollment of Two Ph III Studies of Cystic Fibrosis Drug Combination

Vertex Pharmaceuticals

cystic fibrosis

Flag link:

Pages